IRIS
GORI SAVELLINI, GIANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.455
EU - Europa 3.607
AS - Asia 2.115
SA - Sud America 439
AF - Africa 165
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 4
Totale 10.792
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.390
RU - Federazione Russa 967
SG - Singapore 659
IE - Irlanda 597
CN - Cina 591
IT - Italia 521
GB - Regno Unito 390
BR - Brasile 362
VN - Vietnam 321
SE - Svezia 234
FR - Francia 215
DE - Germania 207
HK - Hong Kong 192
UA - Ucraina 169
FI - Finlandia 146
KR - Corea 100
ZA - Sudafrica 86
IN - India 51
BD - Bangladesh 37
PL - Polonia 33
IQ - Iraq 31
AR - Argentina 30
CA - Canada 30
NL - Olanda 26
CI - Costa d'Avorio 25
ES - Italia 25
JP - Giappone 24
MX - Messico 24
AT - Austria 17
TR - Turchia 17
NG - Nigeria 16
CZ - Repubblica Ceca 13
PK - Pakistan 13
EC - Ecuador 12
CO - Colombia 11
ID - Indonesia 11
SA - Arabia Saudita 9
BE - Belgio 7
EU - Europa 7
MA - Marocco 7
DZ - Algeria 6
KE - Kenya 6
TN - Tunisia 6
CH - Svizzera 5
CL - Cile 5
EG - Egitto 5
IL - Israele 5
PY - Paraguay 5
UY - Uruguay 5
UZ - Uzbekistan 5
AL - Albania 4
AU - Australia 4
TH - Thailandia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HU - Ungheria 3
IR - Iran 3
KZ - Kazakistan 3
LT - Lituania 3
LU - Lussemburgo 3
MY - Malesia 3
NP - Nepal 3
PA - Panama 3
PE - Perù 3
PH - Filippine 3
PT - Portogallo 3
RS - Serbia 3
AM - Armenia 2
AO - Angola 2
BO - Bolivia 2
CY - Cipro 2
ET - Etiopia 2
GR - Grecia 2
HR - Croazia 2
IM - Isola di Man 2
JO - Giordania 2
KG - Kirghizistan 2
LB - Libano 2
LK - Sri Lanka 2
LY - Libia 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
RO - Romania 2
SY - Repubblica araba siriana 2
AF - Afghanistan, Repubblica islamica di 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
EE - Estonia 1
GD - Grenada 1
GI - Gibilterra 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
NI - Nicaragua 1
Totale 10.789
Salva come PNG Salva come JPEG
Città #
Dublin 579
Dallas 491
Fairfield 396
Ashburn 379
Singapore 359
Chandler 303
Moscow 280
Southend 275
Santa Clara 261
Woodbridge 223
Hong Kong 181
Seattle 180
Wilmington 170
Siena 162
Beijing 161
Cambridge 146
Houston 137
San Jose 136
Jacksonville 130
Hefei 106
Princeton 105
Seoul 98
Ho Chi Minh City 94
Ann Arbor 90
Helsinki 88
Los Angeles 83
Johannesburg 73
Milan 70
Council Bluffs 68
Hanoi 68
New York 68
Munich 63
The Dalles 63
Lauterbourg 59
Menlo Park 40
Nanjing 38
Rome 38
São Paulo 38
Fremont 36
Buffalo 30
Warsaw 29
Florence 27
Abidjan 25
Da Nang 25
Boardman 24
San Diego 23
Frankfurt am Main 21
Orem 21
Redondo Beach 21
Chicago 19
London 18
Montreal 18
San Mateo 18
Tokyo 18
Abuja 16
Haiphong 16
Shanghai 16
Atlanta 15
Dong Ket 14
Nanchang 14
Norwalk 14
Turku 14
Bengaluru 13
Lancaster 13
Lappeenranta 13
Rio de Janeiro 13
Baghdad 11
Chennai 11
Columbus 11
Denver 11
Hebei 11
Shenyang 11
Tianjin 11
Vienna 11
Düsseldorf 10
Málaga 10
Phoenix 10
Brooklyn 9
Manchester 9
Nuremberg 9
Poplar 9
Portsmouth 9
San Francisco 8
Venezia 8
Belo Horizonte 7
Biên Hòa 7
Brussels 7
Guangzhou 7
Hải Dương 7
Kunming 7
Amsterdam 6
Barnet 6
City of London 6
Mexico City 6
North Bergen 6
Olomouc 6
Charlotte 5
Erbil 5
Goiânia 5
Guarulhos 5
Totale 7.120
Salva come PNG Salva come JPEG
Nome #
A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease 376
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. 347
Antibody response to SARS-CoV-2 in infected patients with different clinical outcome 277
Immunization with Toscana virus N-Gc proteins protects mice against virus challenge 268
Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro 253
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine 250
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. 241
Comparison of a new prototype immunochromatographic assay and a commercial enzyme-linked immunosorbent assay for the detection of serum antibodies against Toscana virus 224
Immunosuppressive monoclonal antibody to CD64 from patients with long-term stable multiple sclerosis 223
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 223
Efficient delivery of DNA to dendritic cells mediated by influenza virosomes 219
Diagnostic tools for Toscana virus infection 213
Seroprevalence to measles virus after vaccination or natural infection in an adult population, in Italy 213
Identification of a neutralizing epitope on tosv gn glycoprotein 212
Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: Results from a large-scale screening program based on rapid serological testing 210
Retrospective diagnosis of West Nile virus infection in a patient with meningoencephalitis in Tuscany, Italy 203
Toscana virus induces interferon although its NSs protein reveals antagonistic activity. 202
Human Polymorphonuclear Cells Support Zika Virus to Cross Endothelial Monolayer and Access Bloodstream 199
Seroprevalence of antibodies to Sandfly fever Sicilian virus in a sample population in Tuscany, Italy 190
Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine 189
Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector 188
Development of a mouse model for the study of Toscana virus pathogenesis 187
Omicron infection evokes cross-protection against SARS-CoV-2 variants in vaccinees 186
Toscana Virus NSs protein inhibits the induction of type I interferon by interacting with RIG-I. 183
Efficient inactivation of sars-cov-2 and other rna or dna viruses with blue led light 182
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 180
Immunological characterization of Respiratory Syncytial Virus N protein epitopes recognized by human cytotoxic T lymphocytes 176
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection 176
Comparative performance of a new sars-cov-2 rapid detection system 174
Neutralizing antibody response of vaccinees to SARS-CoV-2 variants 172
Nucleotide variability of Toscana virus M segment in strains isolated from clinical cases 170
Ubiquitin and not only unfolded domains drives toscana virus non-structural NSs protein degradation 170
Infectious Toscana virus in seminal fluid of young man returning from Elba Island, Italy 170
Toscana virus non-structural protein NSs acts as E3 ubiquitin ligase promoting RIG-I degradation 168
Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era 163
How long can SARS-CoV-2 persist in human corpses? 163
Epidemiology of Toscana virus in South Tuscany over the years 2011-2019 158
A novel replication deficient paramyxovirus elicits strong virus neutralising antibody and T cell responses in mice. 158
Seronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity 157
Deletion of 82–85 N-Terminal Residues in SARS-CoV-2 Nsp1 Restricts Virus Replication 157
Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 Secretion 153
Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine 153
Dysregulation of intracellular redox homeostasis by the SARS-CoV-2 ORF6 protein 149
Immunoglobulin M seropositivity for Toscana virus in a random population sample in Sicily 144
Toscana virus infects dendritic and endothelial cells opening the way for the central nervous system 144
Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience 141
Serological and molecular detection of Toscana and other Phleboviruses in patients and sandflies in Tunisia 134
Development of a vaccine against hRSV and hPIV3 using a replication deficient Sendai virus vector. 131
SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells 128
CD40L gene assembled to Immune-Reconstituted Influenza Virosome (IRIV) enhances the immunological and protective activity of a CEA anti-cancer vaccine. 120
Degradation of RIG-I and inhibition of IFN-beta induction by Toscana Virus NSs protein. 116
Development of a vaccine against Toscana Virus. 115
Toscana virus epidemiology: from Italy to beyond. 110
null 103
Truncation of the C-terminal region of Toscana Virus NSs protein is critical for interferon-β antagonism and protein stability 103
SARS-CoV-2 n protein targets TRIM25-mediated RIG-I activation to suppress innate immunity 97
null 94
null 94
Seroprevalence and risk factors for Toscana and Sicilian Virus infection in a sample population of Sicily (Italy). 89
In vivo study of the PTH-rP DNA/IRIV vaccine for immune response into humanized transgenic mouse. 79
RIG-I-mediated antiviral signalling is inhibited by toscana virus NSs protein. 77
Toscana virus induces IFN-β production by activation of the cellular sensor RIG-I. 70
Prevalence of Toscana and Sicilian phlebovirus antibodies in classic Kaposi’s sarcoma cases and control subjects in Sicily 65
In vivo study of the PTH-rP DNA/IRIV vaccine for immune response into humanized transgenic mouse. 63
RECOGNITION OF TOSCANA VIRUS NSs REGIONS INVOLVED IN RIG-I DEGRADATION AND IFN-b INHIBITION 62
null 41
Totale 10.945
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.263
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.263
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021179 0 0 0 0 0 0 0 0 0 47 61 71
2021/2022613 34 49 22 30 23 18 32 51 69 55 68 162
2022/20231.036 59 107 135 122 111 224 16 93 100 22 34 13
2023/2024950 29 50 74 73 36 222 341 17 7 12 13 76
2024/20251.933 70 98 177 109 246 129 136 100 210 76 200 382
2025/20263.969 339 576 424 578 830 169 527 136 180 210 0 0
Totale 10.945